Redirect

PMI Chicagoland Chapter is Proud to Present the 6th Annual Career Development Conference -- Resilience & Redirection: Navigating the Future of Project Management

Retrieved on: 
Monday, November 22, 2021
PDU, Coronavirus, Safety, IBM Future Systems project, Conference, AI, Chapter, Redirect, Education, Program, Artificial intelligence, Machine learning, Research, Project Management Institute, Association, Learning, Keynote, CDC, Supply chain, Rapid transit track gauge, Information technology, PMI, Intelligence, Medicine, Public relations

The Chapter invites the public to attend this key event. This year's theme is Resilience & Redirection -- Navigating the Future of Project Management. Event offerings are intended to inform and empower attendees on their individual career plan development, and provide a supportive community to navigate towards the future of the field.

Key Points: 
  • CHICAGO, Nov. 22, 2021 /PRNewswire-PRWeb/ -- The PMI Chicagoland Chapter continues its commitment to the safety and well-being of its member community.
  • This year's theme is Resilience & Redirection -- Navigating the Future of Project Management.
  • Event offerings are intended to inform and empower attendees on their individual career plan development, and provide a supportive community to navigate towards the future of the field.
  • The Keynote address by Kathleen Walch, Managing Partner and Principal Analyst from Cognilytica, is on "Navigating the Future of Project Management with Artificial Intelligence (AI)".

BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure

Retrieved on: 
Monday, November 8, 2021
Cloud, Redirect, Intelligence, Science, Chemical, Biological, Radiological and Explosive Defence Group, Contract manufacturing organization, IIS Metabase, CBRN, Computational biology, Chemical substance, Department, Food, Clarivate, Machine learning, United States Department of Health and Human Services, Artificial intelligence, Multimedia, Microsoft, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, The Science Group, AI, Biomedical Advanced Research and Development Authority, Federal, Partnership, Invention, Vaccine, Office of the Assistant Secretary for Preparedness and Response, Development, Chlorine, Therapy, Solution, Drug discovery, NYSE, Injury, Time, Assistant, Biology, Drive, FDA, Intellectual property, Pharmaceutical industry, Medical device

LONDON, Nov. 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. The new collaboration will leverage Clarivate Consulting Service's computational approach in identifying therapeutics for potential repurposing as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries.

Key Points: 
  • The new collaboration will leverage Clarivate Consulting Service's computational approach in identifying therapeutics for potential repurposing as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries.
  • BARDA funding will aid in target identification and drug factor analyses to identify potential drugs for repurposing to treat chemical agent exposure.
  • Mukhtar Ahmed, President, Science Group, Clarivate, said: "We are honored to be selected to partner with BARDA to identify medical countermeasures to treat chlorine gas exposure and the ocular and respiratory effects of sulfur mustard exposure.
  • The award is one component of BARDA's Chemical, Biological, Radiological, and Nuclear (CBRN) medical countermeasures and DRIVe's ReDIRECT portfolios.

BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure

Retrieved on: 
Monday, November 8, 2021
Cloud, Redirect, Intelligence, Science, Chemical, Biological, Radiological and Explosive Defence Group, Contract manufacturing organization, IIS Metabase, CBRN, Computational biology, Chemical substance, Department, Food, Clarivate, Machine learning, United States Department of Health and Human Services, Artificial intelligence, Microsoft, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, The Science Group, AI, Biomedical Advanced Research and Development Authority, Federal, Partnership, Invention, Vaccine, Office of the Assistant Secretary for Preparedness and Response, Development, Chlorine, Therapy, Solution, Drug discovery, NYSE, Injury, Time, Assistant, Biology, Drive, FDA, Intellectual property, Pharmaceutical industry, Medical device

LONDON, Nov. 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies. The new collaboration will leverage Clarivate Consulting Service's computational approach in identifying therapeutics for potential repurposing as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries.

Key Points: 
  • The new collaboration will leverage Clarivate Consulting Service's computational approach in identifying therapeutics for potential repurposing as medical countermeasures (MCMs) against chlorine and sulfur mustard induced injuries.
  • BARDA funding will aid in target identification and drug factor analyses to identify potential drugs for repurposing to treat chemical agent exposure.
  • Mukhtar Ahmed, President, Science Group, Clarivate, said: "We are honored to be selected to partner with BARDA to identify medical countermeasures to treat chlorine gas exposure and the ocular and respiratory effects of sulfur mustard exposure.
  • The award is one component of BARDA's Chemical, Biological, Radiological, and Nuclear (CBRN) medical countermeasures and DRIVe's ReDIRECT portfolios.

The Media Trust Keeps Publisher Audiences Safe with Expanded Creative-Blocking Capabilities

Retrieved on: 
Thursday, September 9, 2021

MCLEAN, Va., Sept. 9, 2021 /PRNewswire/ -- The Media Trust, global leader in quantifying and managing digital risk, has launched a thoroughly upgraded Media Filter, the fastest and smartest real-time ad-creative blocker for digital media companies.

Key Points: 
  • MCLEAN, Va., Sept. 9, 2021 /PRNewswire/ -- The Media Trust, global leader in quantifying and managing digital risk, has launched a thoroughly upgraded Media Filter, the fastest and smartest real-time ad-creative blocker for digital media companies.
  • With malvertising and sensitive ad content hitting unprecedented levels, Media Filter offers publishers robust tools to keep their audiences safe while also ensuring high-quality ad experiences that won't turn off consumers."
  • The Media Trust is on a mission to make the internet a healthier, more valuable place for publishers and consumers.
  • More than 600 enterprises, media publishers, ad networks/exchanges, and agenciesincluding 40 of comScore's AdFocus Top 50 websitesrely on The Media Trust to protect their website, their employee internet use, their revenue and, most importantly, their brand.